vs
Side-by-side financial comparison of DULUTH HOLDINGS INC. (DLTH) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $114.9M, roughly 1.1× DULUTH HOLDINGS INC.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -9.6%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -31.6%).
Duluth Holdings Inc., which primarily sells goods through its Duluth Trading Company brand, is an American workwear and accessories company.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
DLTH vs TVTX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $114.9M | $129.7M |
| Net Profit | $-10.1M | — |
| Gross Margin | 53.8% | 98.0% |
| Operating Margin | -7.7% | -25.0% |
| Net Margin | -8.8% | — |
| Revenue YoY | -9.6% | 73.4% |
| Net Profit YoY | 64.6% | — |
| EPS (diluted) | $-0.29 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $114.9M | $129.7M | ||
| Q3 25 | $131.7M | $164.9M | ||
| Q2 25 | $102.7M | $114.4M | ||
| Q1 25 | $241.3M | $81.7M | ||
| Q4 24 | $127.1M | $74.8M | ||
| Q3 24 | $141.6M | $62.9M | ||
| Q2 24 | $116.7M | $54.1M | ||
| Q1 24 | $245.6M | $41.4M |
| Q4 25 | $-10.1M | — | ||
| Q3 25 | $1.3M | $25.7M | ||
| Q2 25 | $-15.3M | $-12.8M | ||
| Q1 25 | $-5.6M | $-41.2M | ||
| Q4 24 | $-28.2M | — | ||
| Q3 24 | $-2.0M | $-54.8M | ||
| Q2 24 | $-7.9M | $-70.4M | ||
| Q1 24 | $6.4M | $-136.1M |
| Q4 25 | 53.8% | 98.0% | ||
| Q3 25 | 54.7% | 99.0% | ||
| Q2 25 | 52.0% | 98.7% | ||
| Q1 25 | 44.1% | 94.3% | ||
| Q4 24 | 52.3% | 96.6% | ||
| Q3 24 | 52.3% | 97.4% | ||
| Q2 24 | 52.8% | 96.2% | ||
| Q1 24 | 48.2% | 96.4% |
| Q4 25 | -7.7% | -25.0% | ||
| Q3 25 | 1.8% | 15.1% | ||
| Q2 25 | -12.0% | -11.1% | ||
| Q1 25 | -1.8% | -52.2% | ||
| Q4 24 | -17.4% | -81.2% | ||
| Q3 24 | -1.1% | -89.3% | ||
| Q2 24 | -7.7% | -125.1% | ||
| Q1 24 | 3.6% | -336.5% |
| Q4 25 | -8.8% | — | ||
| Q3 25 | 1.0% | 15.6% | ||
| Q2 25 | -14.9% | -11.1% | ||
| Q1 25 | -2.3% | -50.4% | ||
| Q4 24 | -22.2% | — | ||
| Q3 24 | -1.4% | -87.1% | ||
| Q2 24 | -6.7% | -130.1% | ||
| Q1 24 | 2.6% | -328.9% |
| Q4 25 | $-0.29 | $0.04 | ||
| Q3 25 | $0.04 | $0.28 | ||
| Q2 25 | $-0.45 | $-0.14 | ||
| Q1 25 | $-0.17 | $-0.47 | ||
| Q4 24 | $-0.84 | $-0.71 | ||
| Q3 24 | $-0.06 | $-0.70 | ||
| Q2 24 | $-0.24 | $-0.91 | ||
| Q1 24 | $0.20 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.2M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $160.6M | $114.8M |
| Total Assets | $468.0M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.2M | $93.0M | ||
| Q3 25 | $5.7M | $110.9M | ||
| Q2 25 | $8.6M | $75.2M | ||
| Q1 25 | $3.3M | $61.9M | ||
| Q4 24 | $9.3M | $58.5M | ||
| Q3 24 | $9.8M | $36.4M | ||
| Q2 24 | $6.8M | $32.3M | ||
| Q1 24 | $32.2M | $43.3M |
| Q4 25 | $160.6M | $114.8M | ||
| Q3 25 | $170.0M | $73.6M | ||
| Q2 25 | $167.9M | $32.7M | ||
| Q1 25 | $182.7M | $32.8M | ||
| Q4 24 | $188.1M | $59.1M | ||
| Q3 24 | $215.7M | $-30.5M | ||
| Q2 24 | $218.4M | $15.1M | ||
| Q1 24 | $222.8M | $74.1M |
| Q4 25 | $468.0M | $605.2M | ||
| Q3 25 | $433.8M | $538.6M | ||
| Q2 25 | $463.7M | $555.3M | ||
| Q1 25 | $452.4M | $548.8M | ||
| Q4 24 | $533.1M | $594.1M | ||
| Q3 24 | $488.6M | $504.4M | ||
| Q2 24 | $471.4M | $551.1M | ||
| Q1 24 | $491.2M | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.7M | $60.7M |
| Free Cash FlowOCF − Capex | $-8.9M | — |
| FCF MarginFCF / Revenue | -7.8% | — |
| Capex IntensityCapex / Revenue | 2.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.7M | $60.7M | ||
| Q3 25 | $32.0M | $14.3M | ||
| Q2 25 | $-56.5M | $5.0M | ||
| Q1 25 | $41.2M | $-42.2M | ||
| Q4 24 | $-41.1M | $-35.7M | ||
| Q3 24 | $16.6M | $-42.5M | ||
| Q2 24 | $-33.7M | $-40.2M | ||
| Q1 24 | $69.7M | $-119.0M |
| Q4 25 | $-8.9M | — | ||
| Q3 25 | $29.8M | $14.2M | ||
| Q2 25 | $-57.8M | — | ||
| Q1 25 | $38.7M | — | ||
| Q4 24 | $-43.7M | — | ||
| Q3 24 | $15.0M | — | ||
| Q2 24 | $-35.2M | $-40.3M | ||
| Q1 24 | $60.6M | — |
| Q4 25 | -7.8% | — | ||
| Q3 25 | 22.6% | 8.6% | ||
| Q2 25 | -56.3% | — | ||
| Q1 25 | 16.0% | — | ||
| Q4 24 | -34.4% | — | ||
| Q3 24 | 10.6% | — | ||
| Q2 24 | -30.2% | -74.5% | ||
| Q1 24 | 24.7% | — |
| Q4 25 | 2.0% | — | ||
| Q3 25 | 1.7% | 0.1% | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 1.2% | 0.0% | ||
| Q2 24 | 1.3% | 0.2% | ||
| Q1 24 | 3.7% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 25.40× | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 10.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLTH
| Sales Channel Directly To Consumer | $67.4M | 59% |
| Sales Channel Through Intermediary | $47.4M | 41% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
